Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Beta glucans are polysaccharides found in the cell walls of cereals, bacteria, and fungi, and have been studied for their immunomodulatory effects. Their use in radiation sickness is supported by a modest body of preclinical and limited clinical evidence. Animal studies, particularly in mice, have demonstrated that beta glucans can enhance survival rates after exposure to lethal doses of radiation, primarily by stimulating the recovery of hematopoietic (blood-forming) tissues. For example, research has shown that beta glucans can increase the production of white blood cells, reduce infection risk, and promote healing of damaged tissues following radiation exposure. These effects are attributed to activation of macrophages and other immune cells, as well as antioxidant properties that may mitigate some radiation-induced cellular damage.

However, robust clinical trials in humans are lacking. Most human data are derived from small-scale or adjunctive studies, often in the context of cancer radiotherapy rather than acute radiation syndrome. No beta glucan product is currently approved by regulatory agencies specifically for the treatment or prevention of radiation sickness in humans. The current scientific consensus is that while there is promising preclinical evidence, more rigorous human studies are needed to confirm efficacy and safety. Thus, the use of beta glucans for radiation sickness is scientifically motivated, but the evidence is still relatively preliminary (rated 2/5).

More about Beta Glucans
More about Radiation Sickness

Other ingredients used for Radiation Sickness

Other health conditions supported by Beta Glucans

Products containing Beta Glucans